These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 31418702

  • 1. [Insights on glycated albumin].
    Hay-Lombardie A, Kamel S, Bigot-Corbel E.
    Ann Biol Clin (Paris); 2019 Aug 01; 77(4):407-414. PubMed ID: 31418702
    [Abstract] [Full Text] [Related]

  • 2. Glycated albumin and continuous glucose monitoring to replace glycated haemoglobin in patients with diabetes treated with haemodialysis.
    Meyer L, Chantrel F, Imhoff O, Sissoko A, Serb L, Dorey F, Fleury D, Smagala A, Kepenekian L, Krummel T, Le Floch JP, Kessler L.
    Diabet Med; 2013 Nov 01; 30(11):1388-9. PubMed ID: 23909880
    [No Abstract] [Full Text] [Related]

  • 3. Serum albumin-adjusted glycated albumin reflects glycemic excursion in diabetic patients with severe chronic kidney disease not treated with dialysis.
    Fukami K, Shibata R, Nakayama H, Yamada K, Okuda S, Koga M.
    J Diabetes Complications; 2015 Nov 01; 29(7):913-7. PubMed ID: 26164356
    [Abstract] [Full Text] [Related]

  • 4. Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker.
    Copur S, Siriopol D, Afsar B, Comert MC, Uzunkopru G, Sag AA, Ortiz A, Covic A, van Raalte DH, Cherney DZ, Rossing P, Kanbay M.
    Acta Diabetol; 2021 Jan 01; 58(1):81-91. PubMed ID: 32862262
    [Abstract] [Full Text] [Related]

  • 5. The clinical usefulness of glycated albumin in patients with diabetes and chronic kidney disease: Progress and challenges.
    Gan T, Liao B, Xu G.
    J Diabetes Complications; 2018 Sep 01; 32(9):876-884. PubMed ID: 30049445
    [Abstract] [Full Text] [Related]

  • 6. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring.
    Vos FE, Schollum JB, Coulter CV, Manning PJ, Duffull SB, Walker RJ.
    Nephrology (Carlton); 2012 Feb 01; 17(2):182-8. PubMed ID: 21883672
    [Abstract] [Full Text] [Related]

  • 7. Discordance in the levels of hemoglobin A1C and glycated albumin: Calculation of the glycation gap based on glycated albumin level.
    Kim MK, Yun KJ, Kwon HS, Baek KH, Song KH.
    J Diabetes Complications; 2016 Apr 01; 30(3):477-81. PubMed ID: 26803475
    [Abstract] [Full Text] [Related]

  • 8. Glycated albumin versus glycated hemoglobin as glycemic indicator in hemodialysis patients with diabetes mellitus: variables that influence.
    Sany D, Elshahawy Y, Anwar W.
    Saudi J Kidney Dis Transpl; 2013 Mar 01; 24(2):260-73. PubMed ID: 23538348
    [Abstract] [Full Text] [Related]

  • 9. Serum albumin-adjusted glycated albumin is a better indicator of glycaemic control in diabetic patients with end-stage renal disease not on haemodialysis.
    Fukami K, Shibata R, Nakayama H, Yamada K, Okuda S, Koga M.
    Ann Clin Biochem; 2015 Jul 01; 52(Pt 4):488-96. PubMed ID: 25568140
    [Abstract] [Full Text] [Related]

  • 10. Glycated albumin and ratio of glycated albumin to glycated hemoglobin are good indicators of diabetic nephropathy in type 2 diabetes mellitus.
    Wang N, Xu Z, Han P, Li T.
    Diabetes Metab Res Rev; 2017 Feb 01; 33(2):. PubMed ID: 27537245
    [Abstract] [Full Text] [Related]

  • 11. Superiority of glycated albumin over glycated haemoglobin as indicator of glycaemic control and predictor of all-cause mortality in patients with type 2 diabetes mellitus receiving peritoneal dialysis.
    Miyabe M, Kurajoh M, Mori K, Okuno S, Okada S, Emoto M, Tsujimoto Y, Inaba M.
    Ann Clin Biochem; 2019 Nov 01; 56(6):684-691. PubMed ID: 31411048
    [No Abstract] [Full Text] [Related]

  • 12. Variability in glycated albumin levels predicts the progression of diabetic nephropathy.
    Park SB, Kim SS, Kim IJ, Nam YJ, Ahn KH, Kim JH, Jeon YK, Kim BH, Song SH, Kwak IS, Lee EK, Kim YK.
    J Diabetes Complications; 2017 Jun 01; 31(6):1041-1046. PubMed ID: 28396158
    [Abstract] [Full Text] [Related]

  • 13. Comparison of Glycemic Markers in Chronic Hemodialysis Using Continuous Glucose Monitoring.
    Divani M, Georgianos PI, Didangelos T, Iliadis F, Makedou A, Hatzitolios A, Liakopoulos V, Grekas DM.
    Am J Nephrol; 2018 Jun 01; 47(1):21-29. PubMed ID: 29275415
    [Abstract] [Full Text] [Related]

  • 14. Use of complementary markers in assessing glycaemic control in people with diabetic kidney disease undergoing iron or erythropoietin treatment.
    Konya J, Ng JM, Cox H, Cooke M, Lewis N, Bhandari S, Atkin SL, Kilpatrick ES.
    Diabet Med; 2013 Oct 01; 30(10):1250-4. PubMed ID: 23758176
    [Abstract] [Full Text] [Related]

  • 15. Glycated albumin and the risk of chronic kidney disease in subjects with Type 2 Diabetes: A study in North Indian Population.
    Raghav A, Ahmad J, Noor S, Alam K, Mishra BK.
    Diabetes Metab Syndr; 2018 May 01; 12(3):381-385. PubMed ID: 29396252
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Continuous Glucose Monitoring and Use of Alternative Markers To Assess Glycemia in Chronic Kidney Disease.
    Zelnick LR, Batacchi ZO, Ahmad I, Dighe A, Little RR, Trence DL, Hirsch IB, de Boer IH.
    Diabetes Care; 2020 Oct 01; 43(10):2379-2387. PubMed ID: 32788282
    [Abstract] [Full Text] [Related]

  • 18. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection.
    Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, Okamura M, Okada S, Yamakawa T, Ishimura E, Nishizawa Y, Osaka CKD Expert Research Group.
    J Am Soc Nephrol; 2007 Mar 01; 18(3):896-903. PubMed ID: 17267743
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.